Stock-based Compensation (Tables)

12 Months Ended

Dec. 31, 2018

Categories of Stock-based Compensation Expense

OncoCyte recorded stock-based compensation expense in the following categories on the accompanying statements of operations for the years ended December 31, 2018 and 2017 (in thousands):

	2018		2017
Research and development	$	50	$	668
General and administrative		1,154		841
Sales and marketing		275		121
Total stock-based compensation expense	$	1,479	$	1,630

Schedule of Assumptions Used to Calculate Fair Value of Stock Options

The weighted-average estimated fair value of stock options with service-conditions granted during the years ended December 31, 2018 and 2017 was $1.46 and $3.24 per share, respectively, using the Black-Scholes option pricing model with the following weighted-average assumptions:

	2018			2017
Expected life (in years)		5.65			6.15
Risk-free interest rates		2.85	%		2.03	%
Volatility		75.51	%		66.01	%
Dividend yield		-	%		-	%

Schdule of Stock Options Outstanding

Additional information regarding the Company’s outstanding stock options and vested and exercisable stock options is summarized below:

	As of December 31, 2018
		Options Outstanding
Exercise Prices		(in thousands) Number of Shares	Weighted- Average Remaining Contractual Life (Years)		Weighted- Average Exercise Price
$1.34 - $1.95		554	2.76	$	1.40
$2.01 - $2.85		2,404	7.86		2.30
$3.06 - $7.25		1,574	6.61		4.24
$1.34 - $7.25		4,532	6.80	$	2.87

2010 Plan Activity [Member]

Summary of Stock Option Activity

A summary of OncoCyte stock option activity under the 2010 Plan and related information follows (in thousands except weighted average exercise price):

Options	Shares Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
Balance at January 1, 2017		880			3,017		$	2.52
Increase in pool		1,200			-
Options granted		(896	)		896			5.17
Options exercised		-			(323	)		1.89
Options forfeited, cancelled or expired		200			(200	)		3.11
Balance at December 31, 2017		1,384			3,390			3.25
Options granted		(1,446	)		1,446			2.39
Options exercised		-			(20	)		2.84
Options forfeited, cancelled or expired		138			(645	)		3.96
Termination of the 2010 Plan		(76	)		-			-
Balance at December 31, 2018		-			4,171		$	2.92
Exercisable at December 31, 2018					2,348		$	2.82

2018 Incentive Plan Activity [Member]

Summary of Stock Option Activity

A summary of 2018 Incentive Plan activity and related information follows (in thousands except weighted average exercise price):

Options	Shares Available for Grant			Number of Options Outstanding			Weighted Average Exercise Price
Balance at December 31, 2017		-			-		$	-
Approval of 2018 Incentive Plan		5,000			-			-
Options granted		(411	)		411			2.21
Options exercised		-			-			-
Options forfeited, cancelled or expired		50			(50	)		1.95
Balance at December 31, 2018		4,639			361		$	2.21
Exercisable at December 31, 2018					-		$	-